PDF(Pubmed)
Abstract：
While mortality caused by sepsis remains an unsolved problem, studies showed conflicting results about effectiveness of monoclonal and polyclonal antibodies in patients suffering sepsis. For this reason, this current study provides an update of review clinical randomized trial studies until March 2024. The main object of this study is to determine effects of monoclonal and polyclonal antibodies on mortality rate and hospitalization of patients suffering sepsis. Search of Scopus, Web of science, EMBASE, PubMed and Cochrane were performed and randomized controlled trials which conducted in patients with septic shock or bacterial sepsis were included. Two reviewers assessed all searched trials for eligibility according to already defined criteria and did data collection and analyses afterwards. Present study showed monoclonal and polyclonal antibodies are a safe strategy with mild-to-moderate adverse effects. However, most studies indicate no significant change among inter-and intra-group comparison (p > 0.05) and further studies are needed, results showed an increase in survival rate, ventilator-and ICU-free days, resolve organ dysfunction, mediating inflammation related cytokines.
摘要：
虽然败血症引起的死亡率仍然是一个未解决的问题，研究显示,单克隆抗体和多克隆抗体在脓毒症患者中的有效性结果相互矛盾.出于这个原因,本研究提供了截至2024年3月的回顾临床随机试验研究的最新资料.这项研究的主要目的是确定单克隆和多克隆抗体对脓毒症患者死亡率和住院率的影响。搜索Scopus,WebofScience,EMBASE,进行了PubMed和Cochrane，并纳入了在感染性休克或细菌性败血症患者中进行的随机对照试验。两名审查人员根据已经定义的标准评估了所有搜索试验的资格，并随后进行了数据收集和分析。目前的研究表明，单克隆和多克隆抗体是一种安全的策略，具有轻度至中度的不良反应。然而,大多数研究表明，组间和组间比较没有显著变化(p>0.05)，需要进一步研究，结果显示存活率提高，无呼吸机和ICU的天数，解决器官功能障碍，介导炎症相关细胞因子。
